Basepoint Wealth LLC Gilead Sciences, Inc. Transaction History

Basepoint Wealth LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Oct 16, 2025	SELL	$63.15 - $72.88 $209,594 - $241,888	-3,319 Closed	0 $0
Q1 2024 Oct 16, 2025	SELL	$71.58 - $87.29 $248,525 - $303,070	-3,472 Reduced 51.13%	3,319 $243 Million
Q4 2023 Oct 16, 2025	SELL	$73.27 - $83.09 $279,305 - $316,739	-3,812 Reduced 35.95%	6,791 $550 Million
Q3 2023 Oct 16, 2025	SELL	$73.94 - $80.67 $1,922 - $2,097	-26 Reduced 0.24%	10,603 $795 Million
Q2 2023 Oct 15, 2025	BUY	$76.01 - $86.7 $3,344 - $3,814	44 Added 0.42%	10,629 $819 Million

Q1 2023 Oct 10, 2025	BUY	$77.31 - $88.08 $16,776 - $19,113	217 Added 2.09%	10,585 $878 Million
Q4 2022 Oct 08, 2025	SELL	$62.32 - $89.47 $13,959 - $20,041	-224 Reduced 2.11%	10,368 $890 Million
Q3 2022 Oct 08, 2025	BUY	$59.54 - $68.01 $177,131 - $202,329	2,975 Added 39.06%	10,592 $653 Million
Q2 2022 Oct 08, 2025	BUY	$57.72 - $65.01 $439,653 - $495,181	7,617 New	7,617 $471 Million

2,376

1.01B

8.58M

7.35M

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $156B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

Get notified when there are updates to the investment portfolio of Basepoint Wealth LLC, based on Form 13F filings with the SEC.

Stay updated on Basepoint Wealth LLC with notifications on news.